Charts

21 Nov, 2022
12:00
Seeking Alpha
17 Nov, 2022
23:14
Seeking Alpha

News

26 Nov, 2022
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
23 Nov, 2022
15:10
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $184.23 per unit.
08 Nov, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
04 Nov, 2022
Upgrades Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to Buy. For the ...
03 Nov, 2022
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
02 Nov, 2022
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
01 Nov, 2022
Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in ...
Acadia Pharmaceuticals (ACAD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
27 Oct, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time basis.
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
26 Oct, 2022
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would...
21 Oct, 2022
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options begin trading this week, for the June 2023 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
20 Oct, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
19 Oct, 2022
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
13 Oct, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.
12 Oct, 2022
Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.
06 Oct, 2022
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
04 Oct, 2022
The security could overcome a technical level of resistance, too
Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome. In honor of Rett syndrome awareness month, this October members of the community are encouraged to submit their photos capturing meaningful moments in their lives to RettRevealed.com to be compiled into the unique mosaic art piece.
13 Sep, 2022
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
12 Sep, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead ...
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA (Prescription Drug User Fee Act) action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.
08 Sep, 2022
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the October 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 28th contracts and identified one put and one call contract of particular interest.
07 Sep, 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.
01 Sep, 2022
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options begin trading today, for the October 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new October 14th contracts and identified one put and one call contract of particular interest.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
31 Aug, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded ...
29 Aug, 2022
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up ...
09 Aug, 2022
Acadia Pharmaceuticals Inc(NASDAQ: ACAD)stopped working on two candidates, including a one-time competitor toVertex ...
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday. ACADIA ...
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks ...
08 Aug, 2022
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
Upgrades For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second ...
07 Aug, 2022
05 Aug, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Signs Off Marker ...
Upgrades For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of ...
CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report Since the Covid-19 outbreak first emerged, the ...
TheFDA has issued a Complete Response Letter(CRL) toAcadia Pharmaceuticals Inc(NASDAQ: ACAD) regarding its ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
04 Aug, 2022
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the September 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new September 23rd contracts and identified one put and one call contract of particular interest.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca/Merck's ...
03 Aug, 2022
01 Aug, 2022
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Corsair Gaming Inc (CRSR), where a total volume of 2,811 contracts has been traded thus far today, a contract volume which is representative of approximately 281,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.3% of CRSR's average daily trading volume over the past month, of 517,920 shares..
31 Jul, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions ...
25 Jul, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 8, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
20 Jul, 2022
11:38
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.
19 Jul, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca's Enhertu ...
18 Jul, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for ...
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options begin trading this week, for the March 2023 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
11 Jul, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: ...
23 Jun, 2022
Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the August 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 5th contracts and identified one put and one call contract of particular interest.
22 Jun, 2022
08:49
FinancialContent
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be ...
21 Jun, 2022
HC Wainwrightsays that anegative AdCom voteonAcadia Pharmaceuticals Inc's(NASDAQ: ACAD) perhaps marks ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug. The post Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today? appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. The Dow traded up 2.09% ...
17 Jun, 2022
03 May, 2022
28 Apr, 2022
22:16
Seeking Alpha

Related Articles